The establishment of a regulated market designed to keep cannabis products away from young people, and that provides clear warnings to those specific populations who may be more vulnerable to its effects — coupled with a policy of consumer education — is the best way to protect public health and mitigate consumers’ risks.
The daily administration of CBD (cannabidiol) as an adjunctive therapy mitigates psychotic symptoms in patients with schizophrenia, according to clinical trial data published online ahead of print in The American Journal of Psychiatry.
Two new studies published online today in JAMA (Journal of the American Medical Association) Psychiatry provide little support for previous claims that cannabis exposure is significantly harmful to the developing brain.
Last week, in what is becoming a semi-annual mainstream media ritual, news outlets around the globe published sensational headlines alleging that consuming cannabis will drives people crazy.
Cananbidiol (CBD), a non-psychotropic cannabinoid, alleviates psychotic symptoms and may hold promise as an alternative antipsychotic treatment, according to a review published in the November issue of the journal Neuropsychopharmacology.
Click here to subscribe to NORMLtv and receive alerts whenever new content is added. The…
[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To…
Every Wednesday on NORML SHOW LIVE, Dr. Mitch Earleywine joins us to discuss the latest…